Perioperative Chemoimmunotherapy With Toripalimab for Sinonasal Cancer
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 4
- 主要终点
- Pathologic Treatment Response Rate (pTRR)
研究概览
简要总结
The aim of this research study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab, with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers.
The names of the study drugs used in this research study are:
- Toripalimab (a type of monoclonal antibody)
- Carboplatin (a type of antineoplastic agent)
- Docetaxel (a type of antineoplastic agent)
- Cisplatin (a type of antineoplastic agent)
详细描述
This single-arm, open-label, single-center phase II study is to evaluate the effectiveness and safety of a combination of immunotherapy, using a drug called toripalimab with chemotherapy drugs, Carboplatin and Docetaxel, as a possible treatment before surgery for sinonasal cancers.
Toripalimab binds to the PD-1 receptors on T-cells (immune cells) and prevents them from interacting with PD-L1 and PD-L2 on tumor cells. This stimulates the immune system to fight tumor cells.
The U.S. Food and Drug Administration (FDA) has not approved Toripalimab for sinonasal cancers, but it has been approved for another type of head and neck cancer called nasopharyngeal carcinoma (NPC), in the advanced incurable setting when surgery is no longer possible, or when cancer has spread to parts of the body outside the head and neck region.
Carboplatin and Docetaxel have been approved by the FDA in the advanced incurable setting for other types of head and neck cancer.
The research study procedures include screening for eligibility, in-clinic visits, questionnaires, blood tests, urine tests, X-rays, Computerized Tomography (CT) scans, Magnetic Resonance Imaging (MRI) scans, or Positron Emission (PET) scans, and photographic images of tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must have histologically or cytologically confirmed locoregionally advanced nasal cavity or paranasal sinus cancer including the following histologic subtypes: squamous cell carcinoma (SCC) of any morphologic variation: verrucous, papillary, basaloid, spindle cell, and adenosquamous; or sinonasal undifferentiated carcinoma (SNUC).
- •Participants with SCC should have resectable disease at baseline per the discretion of the treating surgical oncologist(s). *Participants with SNUC can have operable or borderline resectable (definition: resection would been morbid requiring extensive surgery and would have chances of incomplete gross total resection) disease as judged by the treating surgical oncologist(s).
- •Participants must have clinical stage disease as defined below using the 8th (2017) edition of the tumor, node, metastasis (TNM) staging system by the American Joint Committee on Cancer (AJCC) and the Union for International Cancer Control (UICC):
- •T2, N1-3 III
- •T3, any N III, IVA, IVB
- •T4, any N IVA, IVB
- •Participants must be willing to provide blood and tissue pre-treatment and at the time of surgery for pathologic and correlative analyses.
- •Age 18 years or older at the time of informed consent.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0 or
- •Participants must have adequate organ and marrow function as defined below:
- •Absolute neutrophil count ≥1000/mcL
- •Platelets ≥100
- •Total bilirubin ≤institutional upper limit of normal (ULN)
- •AST(SGOT) / ALT (SGPT) ≤3x ULN
- •Creatinine ≤institutional ULN or GFR of ≥50 mL/min/1.73 m2 unless data exists supporting safe use at lower kidney function values, no lower than 30 mL/min/1.73 m2
- •Women of child-bearing potential (WOCBP) and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Contraception use should be maintained until at least 6 months after the last dose of chemotherapy for females and 3 months for males. In addition, contraception use should continue until 4 months after last dose of toripalimab for both males and females.
- •Ability to understand and the willingness to sign a written informed consent document.
排除标准
- •Participants with nasal cavity or paranasal sinus malignancies demonstrating histologies other than SCC or SNUC in the opinion of the reviewing pathologist. Excluded subtypes include: angiosarcomas, rhabdomyosarcomas, lymphomas, olfactory neuroblastomas (esthesioneuroblastomas), melanomas, and meningiomas among others. SNEC or sinonasal neuroendocrine carcinoma is not permitted.
- •Participants with unresectable or inoperable disease as judged by the treating surgical oncologist(s).
- •Participants with known distant metastatic disease (M1 or IVC).
- •Has received prior therapy with an anti-PD-1/L1 agent or any other agent directed to another stimulatory or co-inhibitory T-cell receptor.
- •Has received a live vaccine or live-attenuated vaccine within 30 days prior to the first dose of study drug. Non-live vaccines are permitted.
- •Carries a diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy (in doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study drug.
- •Has a known additional malignancy that is progressing or has required active treatment within the past 2 years. Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ (breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded. Exceptions may be permitted at the discretion of the overall Sponsor-Investigator.
- •Has an active autoimmune disease that has required systemic treatment in past 6 months (with use of a disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is permitted.
- •Has a history of (non-infectious) pneumonitis or interstitial lung disease that required steroids or has current pneumonitis or interstitial lung disease.
- •Has a known history of human immunodeficiency virus (HIV) infection that is uncontrolled. No HIV testing is required unless mandated by local health authority. Patients with well controlled HIV may be eligible if their CD4 T cell count is favorable and their HIV viral load is undetectable.
- •Has a known history of active Hepatitis B (defined as Hepatitis B surface antigen [HBsAg] reactive) or known active Hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
- •Has a history of allogeneic tissue or solid organ transplant.
- •Women who are pregnant or breastfeeding.
研究组 & 干预措施
Arm 1: Toripalimab and Docetaxel Plus Carboplatin (TCD)
-
Baseline visit with imaging
-
Cycles 1 and 2 (21 day cycles)
-
Day 1: Predetermined dose of Toripalimab 1x daily
-
Day 1: Chemotherapy: predetermined dose of Docetaxel 1x daily and Carboplatin 1x daily
-
Tumor assessment by imaging
-
Surgical resection of tumor
干预措施: Toripalimab (Drug)
Arm 1: Toripalimab and Docetaxel Plus Carboplatin (TCD)
-
Baseline visit with imaging
-
Cycles 1 and 2 (21 day cycles)
-
Day 1: Predetermined dose of Toripalimab 1x daily
-
Day 1: Chemotherapy: predetermined dose of Docetaxel 1x daily and Carboplatin 1x daily
-
Tumor assessment by imaging
-
Surgical resection of tumor
干预措施: Carboplatin (Drug)
Arm 1: Toripalimab and Docetaxel Plus Carboplatin (TCD)
-
Baseline visit with imaging
-
Cycles 1 and 2 (21 day cycles)
-
Day 1: Predetermined dose of Toripalimab 1x daily
-
Day 1: Chemotherapy: predetermined dose of Docetaxel 1x daily and Carboplatin 1x daily
-
Tumor assessment by imaging
-
Surgical resection of tumor
干预措施: Docetaxel (Drug)
Arm 2: Post Operative Radiation Therapy + Toripalimab
After pathology assessment, participants with a pathological treatment response of 2 will be assigned radiation therapy per standard practice guidelines and predetermined dose of Toripalimab 1x every 3 weeks for up to 8 cycles (21 day cycles).
-Follow up: every 3 months for 1 year. Imaging at 3 months
干预措施: Toripalimab (Drug)
Arm 2: Post Operative Radiation Therapy + Toripalimab
After pathology assessment, participants with a pathological treatment response of 2 will be assigned radiation therapy per standard practice guidelines and predetermined dose of Toripalimab 1x every 3 weeks for up to 8 cycles (21 day cycles).
-Follow up: every 3 months for 1 year. Imaging at 3 months
干预措施: Radiation Therapy (Radiation)
Arm 3: Post Operative Radiation Therapy With or Without Chemotherapy
After pathology assessment, participants with a pathological treatment response of 2 or less will be assigned standard radiation therapy with or without standard of care Cisplatin-based chemotherapy as recommended per treatment team and standard practice guidelines.
-Follow up: every 3 months for 1 year. Imaging at 3 months
干预措施: Radiation Therapy (Radiation)
Arm 3: Post Operative Radiation Therapy With or Without Chemotherapy
After pathology assessment, participants with a pathological treatment response of 2 or less will be assigned standard radiation therapy with or without standard of care Cisplatin-based chemotherapy as recommended per treatment team and standard practice guidelines.
-Follow up: every 3 months for 1 year. Imaging at 3 months
干预措施: Cisplatin (Drug)
结局指标
主要结局
Pathologic Treatment Response Rate (pTRR)
时间窗: Tumor assessments or scans will be obtained at baseline and 3-months following the end of treatment. Treatment duration is not fixed and this observation time is variable, criteria for discontinuation is outlined in protocol section 5.10.
pTRR is defined as the proportion of participants that experience a complete pathologic response or partial pathologic response during treatment, as defined in the RECIST criteria.
次要结局
- Incidence of Adverse Events [Safety and Tolerability](Adverse events are collected every study visit through study completion, an average of 1 year. Treatment duration is not fixed and this observation time is variable, criteria for discontinuation is outlined in protocol section 5.10.)
- Median Disease-free Survival (DFS)(Tumor assessments or scans will be obtained at baseline and 3-months following the end of treatment. Treatment duration is not fixed and this observation time is variable, criteria for discontinuation is outlined in protocol section 5.10.)
- Median Overall Survival (OS)(Participants will be followed for 1-year (12 months) after completion or removal from protocol therapy or until death, whichever occurs first. Treatment duration is not fixed and this observation time is variable, criteria for discontinuation is outlined)
- Organ Preservation Rate(Up to 42 days.)
- Overall Response Rate (ORR)(Up to 42 days.)
- Correlation between tumor PD-L1 combined positive score (CPS) with pTR(Tumor assessments or scans will be obtained at baseline and 3-months following the end of treatment. Treatment duration is not fixed and this observation time is variable, criteria for discontinuation is outlined in protocol section 5.10)
- Correlation between tumor PD-L1 combined positive score (CPS) with survival outcomes(Participants will be followed for 1-year (12 months) after completion or removal from protocol therapy or until death, whichever occurs first. Treatment duration is not fixed and this observation time is variable per protocol.)
研究者
Kartik Sehgal, MD
Principal Investigator
Dana-Farber Cancer Institute